November 1st 2022
Ritu Salani, MD, MBA, discusses the importance of histological subtyping and molecular profiling in developing treatment strategies and improving outcomes for patients with endometrial cancer.
October 29th 2021
Ritu Salani, MD, MBA, discusses future research opportunities for improving the treatment of patients with recurrent ovarian cancer.
October 4th 2021
Ritu Salani, MD, MBA, discusses the rationale for combinations of immunotherapy and PARP inhibitors in ovarian cancer.
September 22nd 2021
Ritu Salani, MD, MBA, discusses the scope of ongoing research in advanced ovarian cancer.
November 2nd 2020
Ritu Salani, MD, MBA, discusses therapeutic advances in endometrial cancer.
July 8th 2020
Ritu Salani, MD, MBA, discusses the current state of biomarker testing in cervical cancer.
June 11th 2020
Ritu Salani, MD, discusses opportunities for precision medicine in cervical cancer.
June 10th 2020
March 26th 2020
Ritu Salani, MD, provides insight into how to approach selection of chemotherapy in ovarian cancer.
March 7th 2020
Ritu Salani, MD, discusses the progression of upfront ovarian cancer treatment.
January 25th 2020
Ritu Salani, MD, discusses selecting patients with ovarian cancer for primary debulking surgery versus neoadjuvant chemotherapy.
November 22nd 2019
Ritu Salani, MD, discusses considerations for neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer.
November 21st 2019
Ritu Salani, MD, discusses the potential of targeted therapy and immunotherapy in cervical cancer.